Management of atrial fibrillationBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b5216 (Published 23 December 2009) Cite this as: BMJ 2009;339:b5216
- Carmelo Lafuente-Lafuente, consultant, internal medicine1,
- Isabelle Mahé, professor of therapeutics2,
- Fabrice Extramiana, associate professor of cardiology3
- 1Service de Médecine A, Hôpital Lariboisière, Université Paris 7, Paris
- 2Service de Médecine Interne 5, Hôpital Louis Mourier, Université Paris 7, Paris
- 3Service de Cardiologie, Hôpital Lariboisière, Université Paris 7, Paris
- Correspondence to: Dr C Lafuente-Lafuente, Service de Médecine A, Clinique Thérapeutique, Hôpital Lariboisière, Assistance Publique—Hôpitaux de Paris, Université Paris 7 Diderot, 2, rue Ambroise Paré, 75010 Paris, France
Atrial fibrillation is common and highly variable in its clinical presentation and evolution; it causes substantial morbidity and mortality, including impaired quality of life, heart failure, systemic emboli, and stroke
The first priority is to control heart rate (if tachycardia is present) and provide adequate antithrombotic treatment for preventing complications of embolism
Patients with moderate to high risk of stroke require warfarin long term for preventing emboli; aspirin is adequate in patients with low risk of stroke
When a patient should but cannot take warfarin, aspirin plus clopidogrel can be an intermediate option
For long term treatment of atrial fibrillation, rate control matches rhythm control in terms of mortality and major cardiovascular events but has fewer adverse events related to the treatment and fewer hospital admissions
Consider referring for rhythm control younger patients with lone atrial fibrillation, patients with symptomatic atrial fibrillation, and patients with atrial fibrillation secondary to a corrected precipitant
If antiarrhythmic drugs fail to maintain sinus rhythm, percutaneous catheter ablation is an alternative for rhythm control
Atrial fibrillation is the commonest sustained arrhythmia encountered in clinical practice. Its prevalence increases with age, rising from 0.7% in people aged 55-59 years to 18% in those older than 85 years.1 Consequently, the public health burden associated with atrial fibrillation is increasing.w1 The therapeutics of atrial fibrillation is evolving. In recent years, publication of several randomised controlled trials and meta-analyses have improved our understanding of the advantages and inconveniences of rate and rhythm control strategies, and effective, new non-pharmacological treatments have been introduced. New antiarrhythmic and anticoagulant drugs are expected in the near future.
Clinical manifestations of atrial fibrillation: what is important to know?
Atrial fibrillation is characterised by a chaotic electrical activity in the atria that induces an irregular and usually rapid contraction of the ventricles (figure 1⇓). Patients may be asymptomatic; may have mild symptoms, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial